JP2021503497A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503497A5
JP2021503497A5 JP2020545050A JP2020545050A JP2021503497A5 JP 2021503497 A5 JP2021503497 A5 JP 2021503497A5 JP 2020545050 A JP2020545050 A JP 2020545050A JP 2020545050 A JP2020545050 A JP 2020545050A JP 2021503497 A5 JP2021503497 A5 JP 2021503497A5
Authority
JP
Japan
Prior art keywords
composition
composition according
subject
airway
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020545050A
Other languages
English (en)
Japanese (ja)
Other versions
JP7339955B2 (ja
JP2021503497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/061686 external-priority patent/WO2019099946A1/en
Publication of JP2021503497A publication Critical patent/JP2021503497A/ja
Publication of JP2021503497A5 publication Critical patent/JP2021503497A5/ja
Priority to JP2023090905A priority Critical patent/JP7617179B2/ja
Application granted granted Critical
Publication of JP7339955B2 publication Critical patent/JP7339955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020545050A 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法 Active JP7339955B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090905A JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762588300P 2017-11-17 2017-11-17
US62/588,300 2017-11-17
US201862684700P 2018-06-13 2018-06-13
US62/684,700 2018-06-13
PCT/US2018/061686 WO2019099946A1 (en) 2017-11-17 2018-11-16 Stable ascorbic acid compositions and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090905A Division JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2021503497A JP2021503497A (ja) 2021-02-12
JP2021503497A5 true JP2021503497A5 (https=) 2021-12-23
JP7339955B2 JP7339955B2 (ja) 2023-09-06

Family

ID=66539933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545050A Active JP7339955B2 (ja) 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法
JP2023090905A Active JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090905A Active JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Country Status (22)

Country Link
US (4) US11497786B2 (https=)
EP (2) EP4473976A3 (https=)
JP (2) JP7339955B2 (https=)
KR (1) KR102731292B1 (https=)
CN (1) CN111615395B (https=)
AU (2) AU2018367674B2 (https=)
BR (1) BR112020009910A2 (https=)
CA (1) CA3082900A1 (https=)
DK (1) DK3710036T3 (https=)
ES (1) ES3008699T3 (https=)
FI (1) FI3710036T3 (https=)
HR (1) HRP20241746T1 (https=)
HU (1) HUE069510T2 (https=)
IL (1) IL274635B2 (https=)
LT (1) LT3710036T (https=)
MX (2) MX2020005087A (https=)
PH (1) PH12020550645A1 (https=)
PL (1) PL3710036T3 (https=)
PT (1) PT3710036T (https=)
SG (1) SG11202004540QA (https=)
SI (1) SI3710036T1 (https=)
WO (1) WO2019099946A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117644A (ko) 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
CN111413492A (zh) * 2020-04-30 2020-07-14 山东大学 一种用于检测新型冠状病毒covid-2019肺炎的方法及系统
EP3970718A1 (en) * 2020-09-18 2022-03-23 Charité - Universitätsmedizin Berlin New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
US20240337645A1 (en) * 2021-08-04 2024-10-10 The Trustees Of Indiana University Methods of treating compromised lung function and assessing clinical improvement
CN113995744B (zh) * 2021-10-13 2023-03-17 温州肯恩大学 一种组合物及其抗菌应用
IL313997A (en) 2022-01-04 2024-08-01 Renovion Inc Aqueous solution including glutathione salt
WO2023141237A1 (en) * 2022-01-20 2023-07-27 Cell and Molecular Tissue Engineering, LLC Methods and products to detect, minimize and treat trap-related tissue reactions and tissue injury associated with medical devices
WO2024016019A1 (en) * 2022-07-15 2024-01-18 Renovion, Inc. Compositions and methods for treatment of subjects suffering from a sars-cov-2 infection
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606903A (en) 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
US5070085A (en) 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4968716A (en) 1987-04-10 1990-11-06 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4861783A (en) 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US5304724A (en) 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ES2092539T3 (es) 1991-01-10 1996-12-01 Transcend Therapeutics Inc Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
EP0938331B1 (en) 1996-11-01 2002-12-18 XOMA Technology Ltd. Therapeutic uses of bpi protein products in cystic fibrosis patients
EP0957901B1 (en) 1996-12-31 2009-11-18 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5829449A (en) 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
US6415798B1 (en) 1997-09-19 2002-07-09 Thione International, Inc. Antioxidants to neutralize tobacco free radicals
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
KR100390630B1 (ko) 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
DE19935763B4 (de) 1999-07-27 2006-03-02 Jenning, Volkhard, Dr. Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
EP1282416A2 (en) 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
DE60141703D1 (de) 2000-10-16 2010-05-12 Univ Duke Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose
US20020165207A1 (en) 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
WO2002087508A2 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
WO2003051313A2 (en) 2001-12-18 2003-06-26 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
AUPS019802A0 (en) 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
EP1691614B1 (en) 2003-12-04 2013-02-13 University Of Iowa Research Foundation Gallium inhibits biofilm formation
US20050271726A1 (en) 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
DE102004035113A1 (de) 2004-07-20 2006-02-16 Degussa Ag alpha-Liponsäure enthaltende Zusammensetzung bei cystischer Fibrose
JP5112876B2 (ja) 2004-11-07 2013-01-09 エフ. ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
CA2587883A1 (en) 2004-11-17 2006-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusale M Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
EP1868430B1 (en) 2005-04-12 2015-07-08 Cleo Cosmetic and Pharmaceutical Co., LLC Composition and method for in vitro preservation of corneal tissues
US20060258599A1 (en) 2005-04-27 2006-11-16 Melanie Childers Methods and composition for the treatment of cystic fibrosis and related illnesses
WO2006125262A1 (en) 2005-05-24 2006-11-30 Environmental Biotechnology Crc Pty Limited Methods and compositions for regulating biofilm development
WO2007024876A2 (en) 2005-08-24 2007-03-01 The Board Of Trustees Of Leland Stanford Junior University Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
US9333260B2 (en) 2006-05-10 2016-05-10 Laclede, Inc. Compositions and methods for enzymatic treatment of lung disorders
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20100310541A1 (en) 2007-05-25 2010-12-09 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Reducing the Toxicity of Certain Toxins
WO2009001884A1 (ja) 2007-06-26 2008-12-31 Kyowa Hakko Bio Co., Ltd. 酸化型グルタチオン錠
JP2011026204A (ja) 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び/又は治療用組成物
US9918951B2 (en) * 2008-02-05 2018-03-20 Kyowa Hakko Bio Co., Ltd. Method for improving storage stability of glutathione
US9289462B2 (en) 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione
FR2941374B1 (fr) 2009-01-28 2011-03-11 Alaxia Utilisation d'une association synergique d'ions hypothiocyanites et/ou hypohalites et de lactoferrine pour la preparation pour le traitement de la mucoviscidose
US20120093947A1 (en) 2009-02-27 2012-04-19 United States Department Of Veterans Affairs Method of treating reactive airway disease
GB0908174D0 (en) 2009-05-13 2009-06-24 Isis Innovation Steroid containing composition and uses thereof
CN101987195B (zh) 2009-08-06 2012-07-18 重庆市力扬医药开发有限公司 经口腔粘膜吸收的还原型谷胱甘肽药物
IT1401504B1 (it) 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato
WO2012027603A2 (en) 2010-08-26 2012-03-01 Clarity Products, Limited Liability Company Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CN102100904B (zh) 2011-01-25 2013-04-24 成都卓阳生物科技有限公司 还原型谷胱甘肽经皮吸收制剂及其制备方法
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US20130084336A1 (en) 2011-06-27 2013-04-04 Albert Einstein College Of Medicine Of Yeshiva University Enhanced nitric oxide delivery and uses thereof
CN102329370B (zh) 2011-09-22 2015-07-22 山东金城医药化工股份有限公司 还原型谷胱甘肽单钠盐的制备方法
WO2014070769A1 (en) * 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
US20140234397A1 (en) 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
US9913801B2 (en) 2013-02-15 2018-03-13 Your Energy Systems, LLC Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione
ITPD20130052A1 (it) 2013-03-01 2014-09-02 Enologica Vason S P A Procedimento di vinificazione e prodotto per uso enologico atto ad essere utilizzato in detto procedimento di vinificazione
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
WO2016067283A1 (en) 2014-10-30 2016-05-06 Rice Howard Virucidal compositions comprising tannins for nasal and pulmonary administration
WO2016088116A1 (en) 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
AU2017298202A1 (en) 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
KR20230117644A (ko) * 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en) * 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
MX2020005310A (es) 2017-11-21 2020-10-08 Medoncare Pharmaceutical Co Ltd Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
EA202091396A1 (ru) 2017-12-07 2020-09-02 РИВЕН АйПи ХОЛДКО ЭлЭлСи Композиции и способы лечения метаболических состояний
CA3117213A1 (en) 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs

Similar Documents

Publication Publication Date Title
JP2021503497A5 (https=)
IL274635B1 (en) Stable ascorbic acid compositions and methods of using the same
US20080167230A1 (en) Methods and compositions for treating or preventing lesions of the respiratory epithelium
US20120083531A1 (en) Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
US20120058198A1 (en) Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
JPH03501852A (ja) エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法
RS54733B1 (sr) Tritokvalin za upotrebu u tretiranju cistične fibroze
CN1774258A (zh) 肺病治疗
Hodson Antibiotic treatment aerosol therapy
EP3882023A1 (en) Use of 3-(4-hydroxyphenyl)propionic acid in preparation of drugs for preventing and treating respiratory tract infection
Takahashi et al. Effects of indomethacin, dexamethasone, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium
JP2023519853A5 (https=)
CZ299071B6 (cs) Stálý farmaceutický steroidní prostredek pro inhalaci
JP6013450B2 (ja) 慢性閉塞性肺疾患改善剤
KR20130055580A (ko) 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
BARACH et al. Physiologic and antibiotic (penicillin) therapy in chronic hypertrophic pulmonary emphysema
CN115381843B (zh) L-岩藻糖在制备呼吸系统疾病治疗药物中的用途
Ahmad et al. The Orai1 Antagonist, ELD607, Reduces Chronic Neutrophilic Inflammation in βENaC Mice
RU2766246C1 (ru) Способ лечения и реабилитации больных после острых респираторных вирусных инфекций
RU2008102655A (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
Forfar et al. ACUTE OBSTRUCTIVE LARYNGOTRACHEITIS AND LARYNGOTRACHEOBRONCHITIS REPORT OF AN OUTBREAK
CN102686232A (zh) 用于治疗干咳的来自罗望子树种子的多糖聚合物
WO2022009912A1 (ja) 歯髄幹細胞の培養上清を含む、血中酸素飽和度向上又は血中酸素飽和度低下の抑制のための組成物
WO2022005321A1 (en) Inhaled tocilizumab for treating interleukin-6 related respiratory diseases